SlIde Sets

Explore slide sets below to learn more about dolutegravir and Dovato (dolutegravir/lamivudine)

DOVATO

GEMINI 144-wk TND and Blips analysis (IAS 2021)

A summary of the data presented at IAS 2021 on GEMINI 1&2 144-week study on TND and Blips

View slides

DOVATO

STAT (Test and treat) 48-wk study (IAS 2021)

A summary of the data presented at IAS 2021 on the STAT study data at 48 weeks

View slides

DOVATO

SALSA 48-wk study (IAS 2021)

A summary of the data presented at IAS 2021 on SALSA 48-wk data switching to DTG/3TC from CAR

View slides

DOVATO

TANGO 144-week study (IAS 2021)

A summary of the data presented at IAS 2021 on TANGO 144-week study and metabolic parameters

View slides

DOVATO

TANGO 96-week TND and Blips (IAS 2021)

A summary of the data presented at IAS 2021 on TANGO 96 week data for TND and Blips

View slides

DOVATO

TANGO subgroup analysis (CROI 2021)

A summary of the data presented at CROI 2021 from the TANGO on the 96 week subgroup data.

View slides

DOVATO

GEMINI 1&2 subgroup analysis (CROI 2021)

A summary of the data presented at CROI 2021 from the GEMINI 1&2 studies on the 144 week subgroup data.

View slides

DOVATO

GEMINI 1&2 144 week study - HIV Glasgow 2020 Presentation

Learn more about the latest GEMINI 1&2 144 Week study data for Dovato

View slides

DOVATO

Real-world data from URBAN study - HIV Glasgow 2020 Presentation

Learn more about the latest Real-world data from URBAN study for Dovato

View slides

Other resources

Resources

Watch experts in HIV share the details of Dovato studies and watch internal and external experts share their opinions on the latest data.

Resources

Download bite-size infographics on the latest studies and data to help inform your HIV practice.

PM-GB-HVX-WCNT-200021 v2 | June 2021